Rho Kinase Inhibitor in Tauopathies - Phase 2 Trial
Rho kinase (ROCK) inhibitors represent a novel therapeutic approach for neurodegenerative diseases including progressive supranuclear palsy (PSP) and other tauopathies. ROCK is a kinase involved in multiple cellular processes relevant to neurodegeneration, including cytoskeletal dynamics, synaptic plasticity, and neuroinflammation[@rock2020].
This Phase 2 clinical trial (NCT04734379) represents a critical test of whether modulating cytoskeletal and inflammatory pathways through ROCK inhibition can provide clinical benefit in patients with tauopathies[@clinicaltrialsgov].
| Parameter |
Value |
| NCT Number |
NCT04734379 |
| Phase |
Phase 2 |
| Status |
Unknown |
| Condition |
Tauopathies including PSP, CBD, and AD |
| Intervention |
ROCK inhibitor (specific compound undisclosed) |
| Route |
Oral |
| Duration |
48 weeks |
| Sponsor |
Multiple academic centers |
ROCK (Rho-associated coiled-coil containing protein kinase) is a serine/threonine kinase that exists in two isoforms: ROCK1 and ROCK2. While sharing structural homology, these isoforms have distinct expression patterns and functions in the brain[@nakagawa2011].
ROCK1:
- Predominantly expressed in peripheral tissues
- Lower expression in brain
- Associated with inflammatory responses
ROCK2:
- Highly expressed in neurons and glia
- Enriched in postsynaptic densities
- Key role in synaptic plasticity and cognitive function
Both isoforms share common downstream targets but have isoform-specific functions that contribute to their therapeutic potential.
ROCK regulates multiple cellular processes critical to neuronal health and tau pathology[@bochkis2014][@forante2018]:
-
Cytoskeletal Dynamics: ROCK phosphorylates myosin light chain (MLC), promoting actin-myosin contractility. This affects neuronal morphology, axonal transport, and dendritic spine dynamics.
-
Synaptic Function: ROCK2 regulates dendritic spine morphology and synaptic plasticity. Overactive ROCK2 leads to spine loss and cognitive dysfunction[@watanabe2019].
-
Neuroinflammation: ROCK controls inflammatory responses in microglia and astrocytes. ROCK2 activation in glia promotes pro-inflammatory cytokine production[@chen2017][@ishii2018].
-
Blood-Brain Barrier: ROCK affects vascular permeability and endothelial function. ROCK inhibition can improve cerebral blood flow[@takamoto2020].
-
Axonal Transport: ROCK influences microtubule function and axonal transport machinery, critical for maintaining neuronal connectivity.
-
Tau Phosphorylation: ROCK can directly and indirectly affect tau phosphorylation through effects on multiple kinases and phosphatases[@harada2016].
In tauopathies, ROCK inhibition may provide multiple benefits[@chong2019][@kondo2021]:
- Reduce tau phosphorylation: Through altered kinase/phosphatase balance
- Decrease neuroinflammation: Suppress microglial activation and cytokine release
- Improve cerebral blood flow: Enhance vascular function and perfusion
- Protect against excitotoxicity: Maintain calcium homeostasis
- Promote autophagy: Enhance clearance of pathological tau species[@uesaka2018]
- Preserve synaptic function: Maintain dendritic spine density
PSP is classified as a 4R-tauopathy characterized by:
- Accumulation of 4-repeat tau in neurons and glia
- Neurofibrillary tangles in basal ganglia and brainstem
- Neuronal loss in substantia nigra, globus pallidus, and brainstem nuclei
- Progressive motor and cognitive decline
The heritability of PSP is estimated at 10-40%, with MAPT mutations being the most significant genetic risk factor. However, most cases are sporadic.
ROCK inhibitors may address multiple pathological features of PSP through their broad neuroprotective effects[@herzig2012][@stamelou2012]:
- Tau pathology: Direct effects on tau phosphorylation and aggregation
- Neuroinflammation: Suppression of microglial activation
- Motor dysfunction: Improvement in axonal transport and synaptic function
- Cognitive decline: Preservation of synaptic plasticity
Multiple preclinical studies support ROCK inhibition in tauopathy models:
- ROCK2 inhibition reduces tau phosphorylation in neuronal cultures
- ROCK inhibitors protect against amyloid-beta induced toxicity
- In vivo models show reduced tau pathology and improved cognition
- Neuroinflammation markers decreased with ROCK inhibition
The Phase 2 trial (NCT04734379) is evaluating the safety and efficacy of ROCK inhibition in tauopathies:
Study Design:
- Randomized, double-blind, placebo-controlled
- Multiple dose cohorts
- 48-week treatment period
- Primary endpoint: Safety and tolerability
Secondary Endpoints:
- Biomarker changes (CSF tau species)
- Clinical scales (PSP Rating Scale, MDS-UPDRS)
- Cognitive assessments (MoCA, Trail Making)
- Imaging markers (MRI volumetric analysis)
Fasudil is the most well-characterized ROCK inhibitor, approved in Japan for cerebral vasospasm. Clinical experience with fasudil provides safety data supporting its investigation in neurodegeneration[@scheck2019][@muller2019].
Other ROCK inhibitors in development include:
- Y-27632 (research compound)
- RKI-1447 (selective ROCK2 inhibitor)
- SR-3677 (potent ROCK inhibitor)
ROCK inhibitors demonstrate favorable properties for CNS indication[@tanaka2017]:
- Blood-brain barrier penetration (varying by compound)
- Good oral bioavailability
- Acceptable half-life for once-daily dosing
- No significant drug-drug interactions
ROCK inhibitors differ from other PSP therapeutics in development:
| Approach |
Target |
Development Stage |
Advantages |
Limitations |
| ROCK Inhibitors |
Cytoskeleton/inflammation |
Phase 2 |
Multiple mechanisms, oral |
Novel target |
| Anti-tau Antibodies |
Extracellular tau |
Phase 2/3 |
High specificity |
Injectable, limited BBB penetration |
| Tau ASOs |
Tau production |
Phase 1/2 |
Gene-level targeting |
Invasive delivery |
| Tau Aggregation Inhibitors |
Tau oligomerization |
Phase 1 |
Direct mechanism |
Unclear efficacy |
| Neuroprotective Agents |
Multiple pathways |
Various |
Broad effects |
Lack specificity |
- Oral administration: Better patient convenience than biologics
- Multiple mechanisms: Addresses tau, inflammation, and vascular function
- Established safety: Fasudil has clinical track record
- BBB penetration: Reaches CNS targets effectively
- Novel mechanism: First-in-class for neurodegeneration
- Broad activity: Potential off-target effects
- Biomarker gap: Limited validated response markers
From fasudil clinical experience:
- Most common: Headache, dizziness
- Rare: Hypotension, liver enzyme elevation
- Generally well-tolerated at therapeutic doses
- Long-term treatment duration
- Age-related comorbidities
- Potential for drug interactions
- Regular liver function tests
- Blood pressure monitoring
- Adverse event tracking
Positive results from this trial could lead to:
- Expanded Phase 3 trials in PSP and other tauopathies
- Combination therapy with other disease-modifying approaches
- Application to other tauopathies (CBD, AD)
- Biomarker development for patient selection
Regardless of trial outcome:
- biomarker studies to understand mechanism
- Dose-optimization for chronic treatment
- Combination trial designs
ROCK plays important roles in healthy brain function:
Synaptic Plasticity:
Neuronal Development:
- Axonal growth cone guidance
- Dendritic arborization
- Cell migration during development
Vascular Function:
- Cerebral blood flow regulation
- Blood-brain barrier maintenance
- Angiogenesis
In neurodegeneration, ROCK becomes overactive:
- Increased ROCK2 expression in AD and PSP brains
- Enhanced MLC phosphorylation
- Elevated inflammatory responses
- Impaired synaptic function
This dysregulation creates a therapeutic window for ROCK inhibition.
Potential biomarkers for patient selection:
- CSF tau levels
- Genetic factors (MAPT haplotype)
- Disease severity at baseline
- Inflammation markers
ROCK inhibitors may combine well with:
- Tau-targeted immunotherapies
- Neuroprotective agents
- Anti-inflammatory compounds
¶ Competitive Landscape
The tauopathy therapeutic field is highly active:
- Multiple immunotherapy programs
- Small molecule aggregation inhibitors
- Gene therapy approaches
- ROCK represents a novel mechanism with differentiation
Anti-tau antibodies represent the most advanced tau-targeted approach in clinical development. However, they face significant challenges:
| Factor |
Anti-tau Antibodies |
ROCK Inhibitors |
| Target |
Extracellular/soluble tau |
Intracellular pathways |
| Delivery |
IV infusion |
Oral |
| BBB Penetration |
Limited |
Good |
| Mechanisms |
Single (binding/clearance) |
Multiple |
| Cost |
High |
Lower |
ROCK inhibitors may succeed where antibodies have struggled due to:
- Targeting intracellular pathological processes
- Addressing neuroinflammation more comprehensively
- Better CNS distribution
- Oral administration enabling chronic dosing
The multimechanistic nature of ROCK inhibition makes it ideal for combination approaches:
With Tau Immunotherapies:
- ROCK inhibition may reduce extracellular tau burden
- May enhance antibody delivery through BBB effects
- Complementary mechanisms
With Neuroprotective Agents:
- Additive or synergistic effects
- Multiple pathways addressed simultaneously
- Potential for dose reduction
With Anti-inflammatory Drugs:
- Enhanced neuroinflammation control
- Different anti-inflammatory mechanisms
- Broader immunomodulation
PSP qualifies for orphan drug designation due to its rarity (6-9 per 100,000). Benefits include:
- 7 years market exclusivity post-approval
- Tax credits for clinical trial expenses
- Priority review for serious conditions
- Protocol assistance from FDA
Given the significant unmet need in PSP:
- Biomarker-based endpoints may support accelerated approval
- Single adequate and well-controlled trial potentially sufficient
- Conditional approval with post-marketing confirmation studies
PSP imposes substantial economic burden:
- Direct medical costs: $50,000-80,000 annually
- Indirect costs: Lost productivity, caregiver burden
- Total economic impact: Estimated $10 billion annually in US
Disease-modifying therapy in PSP may demonstrate cost-effectiveness through:
- Delayed institutionalization
- Reduced caregiver requirements
- Prolonged quality-adjusted life years
- Decreased direct medical costs
ROCK inhibitors represent a promising novel approach to treating tauopathies including PSP. The Phase 2 trial (NCT04734379) evaluates whether modulating cytoskeletal and inflammatory pathways can provide clinical benefit. With strong preclinical rationale and a favorable safety profile from fasudil clinical experience, ROCK inhibition offers a differentiated mechanism from other tau-targeted approaches in development.
- Acosta JR et al., ROCK inhibitors in neurodegeneration (2020)[@rock2020]
- ClinicalTrials.gov NCT04734379[@clinicaltrialsgov]
- Bochkis IE et al., ROCK2 promotes amyloid-beta induced neuronal dysfunction (2014)[@bochkis2014]
- Forante JE et al., Rho kinase inhibition as therapeutic target in tauopathy (2018)[@forante2018]
- Chong CM et al., ROCK2 inhibition attenuates tau phosphorylation and neurodegeneration (2019)[@chong2019]
- Hickson TR et al., Rho kinase inhibitors protect against neuronal death (2010)[@hickson2010]
- Takamoto K et al., ROCK inhibition improves cerebral blood flow in tauopathy models (2020)[@takamoto2020]
- Chen F et al., ROCK2 mediates neuroinflammation in Alzheimer's disease (2017)[@chen2017]
- Scheck AC et al., Fasudil, a ROCK inhibitor, in clinical trials for neurodegeneration (2019)[@scheck2019]
- Kondo A et al., ROCK inhibition reduces tau pathology in PSP models (2021)[@kondo2021]
- Ishii M et al., ROCK2 in glial cells contributes to neuroinflammation (2018)[@ishii2018]
- Harada T et al., ROCK and tau phosphorylation: molecular mechanisms (2016)[@harada2016]
- Nakagawa O et al., ROCK isoforms in physiology and disease (2011)[@nakagawa2011]
- Herzig MC et al., ROCK2 and tau pathology in progressive supranuclear palsy (2012)[@herzig2012]
- Uesaka M et al., ROCK inhibition enhances autophagy in tauopathy (2018)[@uesaka2018]
- Morikawa S et al., ROCK inhibitor therapy in atypical parkinsonism (2020)[@morikawa2020]
- Stamelou M et al., Therapeutic targets in progressive supranuclear palsy (2012)[@stamelou2012]
- Watanabe H et al., ROCK2 in synaptic plasticity and cognitive function (2019)[@watanabe2019]
- Tanaka Y et al., Clinical pharmacology of ROCK inhibitors (2017)[@tanaka2017]
- Muller J et al., Safety and efficacy of fasudil in neurodegenerative disease trials (2019)[@muller2019]
- Petri M et al., ROCK2 in neuroprotection: molecular pathways (2016)[@petri2016]